

Dany Abi Gerges, MS, MD

Medical Oncologist

Ext. 6422/ 5421

dany.abigerges@laumcrh.com



Dr. Dany Abi Gerges is a medical oncologist with extensive clinical, academic, and research experience in oncology and pharmacology. After beginning his academic journey in engineering, he shifted his focus to medicine, earning a Doctor of Medicine degree from Saint Joseph University (USJ) and a Master's degree in Microbiology from the American University of Beirut (AUB). He began teaching at the USJ Faculty of Medicine during his final year of study, marking the start of a lifelong commitment to medical education. Dr. Abi Gerges completed his residency in Internal Medicine at Hôtel-Dieu de France between 1988 and 1990, followed by advanced residencies in Hematology and Oncology at Institut Gustave Roussy in France, one of Europe's foremost cancer research and treatment centers.

During his tenure there, he undertook a senior residency in Clinical Pharmacology (Oncology), contributing to groundbreaking studies in drug development and cancer therapeutics. His work led to several publications in leading international journals, including first-author research on irinotecan (CPT-11) pharmacology and clinical applications.

Upon returning to Lebanon in 1993, Dr. Abi Gerges built a distinguished career in both clinical practice and hospital leadership. He served as Chief of the Division of Oncology at Rizk Hospital (1998–2004), Chief of the Medical Department at Middle East Institute of Health (2003–2014), and Chief of the Oncology Division at Sacré-Cœur Hospital (2014–2019). Since 2021, he has held the position of Medical Director at MEIH, in parallel with his role as Assistant Clinical Professor at the Lebanese American University (LAU), where he continues to mentor future physicians and advance oncology education.

Dr. Abi Gerges's professional focus includes medical oncology, drug development, and clinical research in cancer therapeutics. His contributions to international oncology research include participation in the Breast Cancer International Research Group (BCIRG 005 and 006 studies) and the Central Europe Cooperative Oncology Group, reflecting his commitment to collaborative, evidence-based cancer care.

A respected member of several professional societies, Dr. Abi Gerges is affiliated with the American Society of Clinical Oncology (ASCO), the European Society for Medical Oncology (ESMO), the American Association for Cancer Research (AACR), and the European Society for Hematology (ESH). His research interests center on optimizing chemotherapy dosing, managing drug toxicities, and improving therapeutic outcomes in breast and gastrointestinal cancers. Dr. Abi Gerges's scientific contributions include landmark publications such as CPT-11–induced Cholinergic Effects in Cancer Patients (JCO, 1993), Irinotecan High-Dose Escalation Using Intensive High-Dose Loperamide to Control Diarrhea (JNCI, 1994), and Phase I and Pharmacologic Studies of the Camptothecin Analog Irinotecan Administered Every Three Weeks in Cancer Patients (JCO, 1995).